Answers are grounded in this paper and cite their sources.
The Neo-Bioscore improves our previously validated staging system and allows its application in ERBB2-positive patients. We recommend that treatment response and biologic markers be incorporated into the American Joint Committee on Cancer staging system.
No takes yet. Share an insight, caveat, or question.
Mittendorf et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: